INNODATA INC

**Signal Note: INOD Position Initiation** Driehaus Capital's $10.5M entry into INOD is notable given the firm's biotech focus, though INOD is primarily a data/document management services provider to pharma and healthcare rather than a drug developer. This positioning likely reflects either (1) conviction in INOD's AI/automation services benefiting biotech clients amid industry cost pressures, or (2) potential M&A activity. Catalyst timing and specific near-term catalysts are unclear from this signal alone; further due diligence on INOD's pipeline of client contracts or margin expansion would be warranted.